20-409 - KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Status: openA Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Patients with Non-Small Cell Lung Cancer
Contact Us
If you have questions about this trial or are interested in participating, please contact Wendy Blount, director of clinical trials, at (251) 445-9834 or wlblount@health.southalabama.edu.
Description
Lung cancer patients with certain mutations in the KEAP1 or NRF2 gene are known to not respond as well to standard immunochemotherapy (treatment that helps the body’s immune system fight cancer in addition to standard chemotherapy) compared with patients who do not have these mutations. This study will test whether an investigational study drug called telaglenastat (CB-839) will be safe and potentially effective for non-small cell lung cancer (NSCLC) when combined with the FDA approved immunochemotherapy regimen of pembrolizumab, carboplatin, and pemetrexed. The combination of telaglenastat, pembrolizumab, carboplatin, and pemetrexed is investigational. All participants in this study will receive the approved recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed.
Sponsors
This trial is sponsored by Calithera.Providers Associated With This Trial
![Persing brian]()
View ProfileBrian E. Persing, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology
